As filed with the Securities and Exchange Commission on May 23, 2024
Registration No. 333-278131
Registration No. 333-270768
Registration No. 333-263832
Registration No. 333-256185
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-278131
Post-Effective Amendment No. 1 to Form
S-8 Registration Statement No. 333-270768
Post-Effective Amendment No. 1 to Form S-8 Registration Statement
No. 333-263832
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-256185
FORM S-8 POS
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Landos Biopharma, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
Delaware |
|
81-5085535 |
(State or other jurisdiction of
Incorporation or organization) |
|
(I.R.S. Employer
Identification No.) |
P.O. Box 11239
Blacksburg, VA 24062
(Address of principal executive offices)
2019 Equity Incentive Plan
2021 Employee Stock Purchase Plan
2022 Inducement Plan
(Full titles of the plans)
Gregory Oakes
Chief
Executive Officer
Landos Biopharma, Inc.
P.O. Box 11239
Blacksburg, VA 24062
(Name and address of agent for service)
(540) 218-2232
(Telephone number, including area code, of agent for service)
Copies to:
Eric
Blanchard
Madison A. Jones
Cooley LLP
500 Boylston
St,
Boston, MA 02116
(617) 937-2300
Indicate by
check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large
accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐